var data={"title":"Tenofovir and adefovir for the treatment of chronic HBV infection","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Tenofovir and adefovir for the treatment of chronic HBV infection</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/contributors\" class=\"contributor contributor_credentials\">Anna SF Lok, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/contributors\" class=\"contributor contributor_credentials\">Rafael Esteban, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate</a>, <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a>, and <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> are nucleotide reverse transcriptase inhibitors (NRTIs) that are used for the treatment of chronic hepatitis B virus (HBV) infection. However, tenofovir has generally replaced adefovir because it is more potent.</p><p>This topic will focus on the efficacy and safety of NRTIs for the treatment of patients infected with HBV alone. Topic reviews that provide additional information on the treatment of HBV, as well as the use of tenofovir for the treatment of HIV, are presented elsewhere. (See <a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management\" class=\"medical medical_review\">&quot;Hepatitis B virus: Overview of management&quot;</a> and <a href=\"topic.htm?path=treatment-of-chronic-hepatitis-b-in-the-hiv-infected-patient\" class=\"medical medical_review\">&quot;Treatment of chronic hepatitis B in the HIV-infected patient&quot;</a> and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;</a> and <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589706088\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Tenofovir'</a>.) </p><p class=\"headingAnchor\" id=\"H1189182665\"><span class=\"h1\">TENOFOVIR</span></p><p class=\"headingAnchor\" id=\"H2071463476\"><span class=\"h2\">Formulations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate, which is administered orally as the prodrug <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) or <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> (TAF). The intracellular, pharmacologically active moiety is tenofovir-diphosphate. TDF (300 mg daily) has been used extensively for the treatment of HIV and chronic hepatitis B virus (HBV) infection. The newer formulation of tenofovir, TAF (25 mg daily), is also effective for the treatment of HIV and HBV and has fewer adverse effects on renal function and bone density [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/1,2\" class=\"abstract_t\">1,2</a>]. (See <a href=\"#H7\" class=\"local\">'Safety'</a> below.)</p><p class=\"headingAnchor\" id=\"H1621336408\"><span class=\"h2\">Effect of tenofovir disoproxil fumarate on virologic outcomes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is extensive experience demonstrating the virologic efficacy of <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) for the treatment of chronic HBV. TDF is effective regardless of the patient's HBeAg status, the presence or absence or cirrhosis, or prior use of nucleos(t)ide analogues.</p><p>A positive response to treatment is characterized by suppression of HBV DNA and loss of hepatitis B e antigen (HBeAg) (in patients who were initially HBeAg positive). This is followed by loss of hepatitis B surface antigen (HBsAg) in some patients during the course of follow-up.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h3\">Patients with HBeAg-positive chronic hepatitis B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TDF is effective for the treatment of chronic HBV in patients who are HBeAg-positive. However, patients in the immune-tolerant phase of infection (ie, a high viral load, and a normal alanine aminotransferase [ALT]) should generally not be treated because efficacy is lower in this setting. Indications for the treatment of chronic HBV are discussed elsewhere. (See <a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management#H3458586686\" class=\"medical medical_review\">&quot;Hepatitis B virus: Overview of management&quot;, section on 'Indications for antiviral therapy'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The largest study in nucleoside-na&iuml;ve patients included 266 patients with HBeAg-positive chronic HBV who were randomly assigned to TDF (300 mg) or <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> (10 mg) in a ratio of 2:1 [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Significantly more patients who received TDF achieved an HBV DNA level of &lt;400 <span class=\"nowrap\">copies/mL</span> (approximately 80 international <span class=\"nowrap\">units/mL;</span> 76 versus 13 percent), ALT normalization (68 versus 54 percent), and HBsAg loss (3 versus 0 percent) at week 48. The proportion of patients achieving a &ge;2-point reduction in the Knodell necroinflammatory score without worsening fibrosis was similar (74 versus 68 percent), as was the proportion of patients achieving HBeAg seroconversion (21 versus 18 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A follow-up study of the one described above included data on 248 HBeAg-positive patients who received open-label TDF [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/5\" class=\"abstract_t\">5</a>]. Among these 248 patients, including those who dropped out or discontinued therapy, 65 percent had an HBV DNA level &lt;400 <span class=\"nowrap\">copies/mL</span> (approximately 80 international <span class=\"nowrap\">units/mL)</span> after five years of treatment. However, of the patients who remained on treatment and were available for assessment at the end of year 5, 97 percent achieved an HBV DNA of &lt;169 <span class=\"nowrap\">copies/mL</span> (approximately 34 international <span class=\"nowrap\">units/mL)</span> and 49 percent became HBeAg negative. At year 7, 160 patients remained on treatment and were available for assessment; all but one had an HBV DNA &lt;29&nbsp;international <span class=\"nowrap\">units/mL,</span> and 55 percent became HBeAg negative [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/6\" class=\"abstract_t\">6</a>]. HBsAg loss occurred in 23 patients by year 5 and in 25 patients by year 7.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TDF was also effective in suppressing HBV DNA in another randomized trial of 126 treatment-na&iuml;ve patients who had a positive HBeAg, a high viral load, and a normal ALT (ie, patients in the immune-tolerant phase of infection) [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/7\" class=\"abstract_t\">7</a>]. At week 192, TDF suppressed HBV DNA levels to &lt;69 international <span class=\"nowrap\">units/mL</span> in 55 percent of patients (if TDF was used as monotherapy) or 76 percent (if combined with <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>). However, only three patients underwent HBeAg seroconversion (all in the TDF monotherapy group) and none lost HBsAg. Posttreatment follow-up after discontinuing therapy was provided for 52 patients; all but one had a rapid increase in HBV DNA within four weeks, and one patient had a hepatitis flare defined as an increase in ALT to greater than 10 times the upper limit of normal.</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h3\">Patients with HBeAg-negative chronic hepatitis B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TDF is also effective for the treatment of chronic HBV in patients who are HBeAg negative. The largest study in nucleoside-na&iuml;ve patients included 375 patients with HBeAg-negative chronic HBV who were randomly assigned to TDF (300 mg) or <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> (10 mg) in a ratio of 2:1 [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/3,4\" class=\"abstract_t\">3,4</a>]. At week 48, significantly more patients receiving TDF achieved a serum HBV DNA level of &lt;400 <span class=\"nowrap\">copies/mL</span> (approximately 80 international <span class=\"nowrap\">units/mL;</span> 93 versus 63 percent). The proportion of patients achieving ALT normalization was similar (77 versus 78 percent), as was the proportion of patients achieving a &ge;2-point reduction in the Knodell necroinflammatory score without worsening of fibrosis (72 versus 69 percent). No patient lost HBsAg. Safety and tolerability were similar.</p><p>A follow-up report described the outcomes of 350 HBeAg-negative patients who received open-label TDF [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/5\" class=\"abstract_t\">5</a>]. After five years of treatment, 87 percent had an HBV DNA level &lt;400 <span class=\"nowrap\">copies/mL</span> based upon an intention-to-treat analysis where patients lost to follow-up were considered nonresponders. However, among those patients who remained on therapy during the follow-up period, and were available for assessment, 99 percent achieved viral suppression. At year 7, viral suppression was maintained in 99 percent and one patient lost HBsAg [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Patients with previous exposure to other nucleos(t)ide analogues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tenofovir (TDF or <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> [TAF]) should be used to treat patients who have previous exposure to other nucleoside analogues. Most studies have evaluated TDF in patients with lamivudine- or adefovir-resistant virus. However, tenofovir should also be effective in patients with prior exposure to <a href=\"topic.htm?path=telbivudine-united-states-not-available-drug-information\" class=\"drug drug_general\">telbivudine</a> or <a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">entecavir</a>, but data are more limited. A discussion of the management of patients with previous exposure to nucleos(t)ide analogues is presented elsewhere. (See <a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management#H2368395154\" class=\"medical medical_review\">&quot;Hepatitis B virus: Overview of management&quot;, section on 'Persistent viremia/breakthrough infection'</a>.)</p><p class=\"headingAnchor\" id=\"H796804192\"><span class=\"h4\">Lamivudine resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies have shown viral suppression with TDF in patients with lamivudine-resistant virus [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/8-14\" class=\"abstract_t\">8-14</a>]. TDF monotherapy is effective in providing sustained viral suppression; multiple studies have shown that combining TDF with <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a> does not appear to provide any additional benefit. As an example, in a randomized study of 280 patients with <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> resistance who were treated with TDF, with or without emtricitabine, the majority of patients (88 percent at 96 weeks and 83 percent at 240 weeks) had an undetectable HBV DNA (&lt;69 international <span class=\"nowrap\">units/mL)</span> [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/11,14\" class=\"abstract_t\">11,14</a>]. There was no additional benefit in those who received combination therapy, and no patient developed tenofovir resistance. (See <a href=\"#H3583698056\" class=\"local\">'Risk of resistance'</a> below.)</p><p>TDF has superior efficacy compared with <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> in patients with lamivudine-resistant HBV [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/15-17\" class=\"abstract_t\">15-17</a>]. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 53 lamivudine-resistant patients all of those who were switched to TDF achieved viral suppression by 48 weeks, whereas only 44 percent of those who were switched to <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> achieved viral suppression [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another study, 19 of 20 patients with chronic HBV infection who had viral breakthrough during <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> therapy, and persistent viral replication after 15 months of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a>, achieved an HBV DNA &lt;400 <span class=\"nowrap\">copies/mL</span> within a median of 3.5 months after being switched to TDF [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/15\" class=\"abstract_t\">15</a>]. Six of the patients had lamivudine resistance mutations at baseline.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Case reports have described viral rebound when patients with undetectable HBV DNA on TDF were switched to <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/17,18\" class=\"abstract_t\">17,18</a>].</p><p/><p>TDF is also superior to <a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">entecavir</a> for patients with lamivudine-resistant HBV, as resistance to <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> constitutes the first step in a two-hit pathway to entecavir resistance. Entecavir resistance is discussed separately. (See <a href=\"topic.htm?path=entecavir-in-the-treatment-of-chronic-hepatitis-b-virus-infection#H11\" class=\"medical medical_review\">&quot;Entecavir in the treatment of chronic hepatitis B virus infection&quot;, section on 'Resistance'</a>.)</p><p class=\"headingAnchor\" id=\"H796804199\"><span class=\"h4\">Adefovir resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TDF and <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> share similarities in chemical structure, and in-vitro studies have shown that while susceptibility of TDF is largely unchanged with single-resistance mutations <span class=\"nowrap\">A181T/V</span> or N236T to adefovir, susceptibility is lower when both mutations are present.</p><p>Clinically, most studies have found that TDF is effective in suppressing HBV replication in patients with adefovir-resistant HBV [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/19,20\" class=\"abstract_t\">19,20</a>]. In a prospective study of 105 adefovir-experienced patients who had an incomplete response to <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a>, patients were randomly assigned to receive TDF alone or with <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a> [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/20\" class=\"abstract_t\">20</a>]. At baseline, 29 had genotypic resistance to adefovir (13 had both lamivudine- and adefovir-associated mutations). Eighty-three percent of patients achieved an undetectable HBV DNA (&lt;69 international <span class=\"nowrap\">units/mL)</span> after 168 weeks of treatment, and the presence of baseline adefovir-associated mutations did not affect response.</p><p>However, some studies have observed a slower decline in HBV DNA levels in patients with N236T mutation particularly if present along with <span class=\"nowrap\">A181T/V</span>. As an example, early reports suggested that patients with adefovir-resistant HBV experience partial viral suppression after switching to TDF with persistence of adefovir-resistant mutations [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/21,22\" class=\"abstract_t\">21,22</a>]. In addition, in a retrospective study of 131 patients with chronic HBV infection resistant to <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a>, TDF therapy was less effective in suppressing HBV DNA (&lt;400 <span class=\"nowrap\">copies/mL)</span> among patients who had adefovir-resistant virus compared with those who had lamivudine-resistant virus (52 versus 100 percent) after a mean treatment duration of 23 months [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/10\" class=\"abstract_t\">10</a>]. An additional discussion of adefovir resistance is found below. (See <a href=\"#H2636208061\" class=\"local\">'Development of resistance'</a> below.)</p><p class=\"headingAnchor\" id=\"H1121393047\"><span class=\"h3\">Patients with spontaneous exacerbation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TDF has been used in patients with severe spontaneous exacerbations of chronic HBV. In a placebo-controlled trial involving 27 patients with a severe spontaneous exacerbation (characterized by the presence of a total bilirubin &ge;5 <span class=\"nowrap\">mg/dL</span> [85.5 <span class=\"nowrap\">micromol/L]</span> and an international normalized ratio&nbsp;[INR] &gt;1.5), treatment with TDF (300 mg daily) was associated with significantly better three-month survival (57 versus 15 percent) [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/23\" class=\"abstract_t\">23</a>]. A favorable outcome was predicted by more than a two-log reduction in HBV DNA levels after two weeks of treatment. (See <a href=\"topic.htm?path=hepatitis-b-virus-clinical-manifestations-and-natural-history#H9\" class=\"medical medical_review\">&quot;Hepatitis B virus: Clinical manifestations and natural history&quot;, section on 'Immune-active, HBeAg-positive (replicative phase)'</a>.)</p><p>Tenofovir can also be used to prevent and treat HBV reactivation in patients receiving immunosuppressive therapy. A discussion of HBV reactivation is found elsewhere. (See <a href=\"topic.htm?path=hepatitis-b-virus-reactivation-associated-with-immunosuppressive-therapy\" class=\"medical medical_review\">&quot;Hepatitis B virus reactivation associated with immunosuppressive therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">In combination with other drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Data on the use of TDF combined with <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a> in treatment-na&iuml;ve patients and those refractory to other therapy are presented above. (See <a href=\"#H2\" class=\"local\">'Patients with HBeAg-positive chronic hepatitis B'</a> above and <a href=\"#H5\" class=\"local\">'Patients with previous exposure to other nucleos(t)ide analogues'</a> above.) </p><p>Additional discussions of combination therapy are found elsewhere. (See <a href=\"topic.htm?path=combination-therapy-for-chronic-hepatitis-b-virus-infection\" class=\"medical medical_review\">&quot;Combination therapy for chronic hepatitis B virus infection&quot;</a> and <a href=\"topic.htm?path=standard-and-pegylated-interferon-for-chronic-hepatitis-b-virus-infection#H769046242\" class=\"medical medical_review\">&quot;Standard and pegylated interferon for chronic hepatitis B virus infection&quot;, section on 'Combination with other nucleos(t)ide analogues'</a>.)</p><p class=\"headingAnchor\" id=\"H1580558325\"><span class=\"h2\">Effect of tenofovir alafenamide on virologic outcomes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">Tenofovir alafenamide</a> (TAF) has been evaluated in HBeAg-positive and HBeAg-negative patients with chronic HBV. This agent has been found to have similar efficacy to <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) in both treatment-na&iuml;ve and treatment-experienced patients at 48 weeks. However, TAF is associated with less renal and bone toxicity compared with TDF since it achieves lower plasma tenofovir exposures, but higher peripheral blood mononuclear cell intracellular tenofovir-diphosphate concentrations. The data reviewing the toxicity of this agent are found below. (See <a href=\"#H7\" class=\"local\">'Safety'</a> below.)</p><p>Two large, multi-center, randomized controlled studies (one in HBeAg-positive and the other in HBeAg-negative patients) were conducted to compare the efficacy of TAF (25 mg daily) with TDF (300 mg daily) in a 2:1 ratio; in both trials, approximately one-quarter of patients had received previous therapy with one or more nucleos(t)ide analogues. The results are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HBeAg-positive patients</strong> &ndash; In this trial, 873 HBeAg-positive patients were enrolled [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/1\" class=\"abstract_t\">1</a>]. Of the 581 who received TAF, 371 (64 percent) had an HBV DNA &lt;29 international <span class=\"nowrap\">units/mL</span> at 48 weeks compared with 195 of the 292 (67 percent) patients who received TDF (adjusted difference, &ndash;3.6 percent; 95% CI &ndash;9.8-2.6). Among those with available data at 48 weeks, approximately 70 percent in each group normalized their ALT. In those who received TAF, HBeAg loss occurred in 78 (14 percent) and HBsAg loss was seen in four patients. This was similar to those who received TDF, where 34 (12 percent) had HBeAg loss and one had loss of HBsAg.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>HBeAg-negative patients </strong>&ndash; This trial was conducted in 425 HBeAg-negative patients with an HBV DNA &gt;20,000 international <span class=\"nowrap\">units/mL</span> and an elevated ALT (&gt;60 <span class=\"nowrap\">units/L</span> in men, &gt;38 <span class=\"nowrap\">units/L</span> in women) [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/2\" class=\"abstract_t\">2</a>]. At week 48, 268 of the 285 patients (94 percent) who received TAF had an HBV DNA &lt;29 international <span class=\"nowrap\">units/mL</span> compared with 130 of the 140 (93 percent) who received TDF (difference, 1.8 percent; 95% CI &ndash;3.6-7.2). There was no significant difference in ALT normalization between the groups (83 versus 75 percent for TAF and TDF, respectively), and no patient had loss of HBsAg during the study period.</p><p/><p class=\"headingAnchor\" id=\"H1630287554\"><span class=\"h2\">Effect on clinical outcomes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the extensive use of <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF), studies have evaluated the impact of this agent on clinical outcomes, such as cirrhosis, fibrosis, and hepatocellular carcinoma.</p><p class=\"headingAnchor\" id=\"H2794773517\"><span class=\"h3\">Regression of fibrosis and cirrhosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early studies of TDF found that approximately 70 percent of patients achieved a &ge;2-point reduction in the Knodell necroinflammatory score without worsening fibrosis by 48 weeks [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/3,4\" class=\"abstract_t\">3,4</a>]. (See <a href=\"#H2\" class=\"local\">'Patients with HBeAg-positive chronic hepatitis B'</a> above and <a href=\"#H3\" class=\"local\">'Patients with HBeAg-negative chronic hepatitis B'</a> above.)</p><p>A study evaluating the more long-term effects of TDF followed 489 patients over 240 weeks [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/5\" class=\"abstract_t\">5</a>]. Of the 348 patients who had a biopsy done at baseline and week 240, 304 (87 percent) had histologic improvement and 176 (51 percent) had regression of fibrosis, defined as a decrease of at least 1 point in Ishak score (range 0 to 6). Of the 96 patients that had cirrhosis at baseline, almost all had an improvement in the Knodell necroinflammatory score of &ge;1 unit; in addition, 71 (74 percent) no longer had cirrhosis [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/5,24\" class=\"abstract_t\">5,24</a>]. However, three patients without cirrhosis progressed to cirrhosis at year 5.</p><p class=\"headingAnchor\" id=\"H2409414740\"><span class=\"h3\">Reduced risk of hepatocellular carcinoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nucleos(t)ide analogues can reduce the risk of developing hepatocellular carcinoma (HCC) [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/25\" class=\"abstract_t\">25</a>]. Although there are no randomized studies evaluating the effect of TDF on the incidence of HCC, a prospective study evaluated the incidence of HCC in 634 patients with chronic HBV (482 without cirrhosis and 152 with cirrhosis) who were treated with TDF in the phase III trial cited above, and were followed for 384 weeks [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/26\" class=\"abstract_t\">26</a>]. Over the course of the study, 14 cases of HCC developed (four within the first year). Among those without cirrhosis, the observed incidence of HCC was significantly lower than the incidence that was predicted using the Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) model (standardized incidence ratio 0.40, 95% CI 0.199-0.795). In addition, no cases of HCC occurred in patients with cirrhosis after week 192.</p><p class=\"headingAnchor\" id=\"H3583698056\"><span class=\"h2\">Risk of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among patients receiving <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate</a> (TDF) for the treatment of chronic HBV infection, no signature mutation for tenofovir resistance has been identified, even after eight years of treatment [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/27-29\" class=\"abstract_t\">27-29</a>]. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among 641 treatment-na&iuml;ve patients treated with TDF over an eight-year period, 88 (14 percent) qualified for sequence analysis (eg, persistent viremia or virologic breakthrough). There was no evidence of tenofovir resistance, and of the 41 episodes of virologic breakthrough, the majority were associated with nonadherence [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/29\" class=\"abstract_t\">29</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 280 patients with chronic HBV and <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> resistance who received TDF alone, or with <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>, no resistance to TDF was detected through 240 weeks of treatment [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p>However, in two cases in which patients had persistent viremia while receiving therapy with tenofovir and <a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">entecavir</a>, molecular analyses identified a distinct mutation, <span class=\"nowrap\">rtS78T/sC69,</span> which was associated with decreased susceptibility to both tenofovir and entecavir in vitro [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/30\" class=\"abstract_t\">30</a>]. The prevalence and significance of this mutation remains to be determined. Another study reported an alanine-to-threonine substitution (rtA194T) in two patients with <span class=\"nowrap\">HIV/HBV</span> coinfection who had prior <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> resistance, and one had virologic breakthrough [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/31\" class=\"abstract_t\">31</a>], but this association was not confirmed [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/32\" class=\"abstract_t\">32</a>].</p><p>The management of patients with persistent viremia while receiving tenofovir is discussed elsewhere. (See <a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management#H1736278503\" class=\"medical medical_review\">&quot;Hepatitis B virus: Overview of management&quot;, section on 'While receiving tenofovir or entecavir'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Safety</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major adverse events associated with tenofovir include renal insufficiency, renal tubular dysfunction, and decreased bone density.</p><p class=\"headingAnchor\" id=\"H796804526\"><span class=\"h3\">Renal insufficiency and renal tubular dysfunction</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate</a><strong> (TDF)</strong> &ndash; TDF is associated with worsening kidney function in some patients. If possible, TDF should be avoided in patients with reduced kidney function. The approach to treatment of chronic HBV in such patients is presented elsewhere. (See <a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management#H1024602452\" class=\"medical medical_review\">&quot;Hepatitis B virus: Overview of management&quot;, section on 'Choice of initial agent'</a>.)</p><p/><p class=\"bulletIndent1\">Patterns of kidney injury due to TDF include proximal tubular dysfunction, acute kidney injury, and chronic kidney disease. This can lead to renal impairment characterized by increases in serum creatinine, proteinuria, glycosuria, hypophosphatemia, and acute tubular necrosis. In HIV-infected patients, TDF has also been reported to cause a Fanconi syndrome with serious complications, including end-stage renal disease and death [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/33-35\" class=\"abstract_t\">33-35</a>]. (See <a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv#H1589706088\" class=\"medical medical_review\">&quot;Overview of antiretroviral agents used to treat HIV&quot;, section on 'Tenofovir'</a>.)</p><p/><p class=\"bulletIndent1\">There are case reports of renal failure developing in patients with HBV monoinfection taking TDF [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/36\" class=\"abstract_t\">36</a>]. Large-scale treatment trials and observational studies have reported low rates of renal toxicity (&lt;2 percent) in such patients [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/37-39\" class=\"abstract_t\">37-39</a>]. In a meta-analysis of 11 studies that compared <a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">entecavir</a> versus TDF in 1300 patients, no statistically significant differences were found between these agents with regards to renal safety or hypophosphatemia over approximately 18 months [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/40\" class=\"abstract_t\">40</a>]. However, in one trial that followed 280 patients on TDF for 240 weeks, renal toxicity (defined as a confirmed change in serum creatinine of 0.5 <span class=\"nowrap\">mg/dL</span> from baseline, a decrease in creatinine clearance [CrCL] &lt;50 <span class=\"nowrap\">mL/min,</span> <span class=\"nowrap\">and/or</span> serum phosphorus &lt;2 <span class=\"nowrap\">mg/dL)</span> developed in approximately 8 percent of patients [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"bulletIndent1\">The decision to initiate <span class=\"nowrap\">and/or</span> discontinue TDF in patients with kidney disease depends upon whether or not the patient is HBV treatment-na&iuml;ve prior to starting TDF, the severity of renal disease, and the availability of alternative agents. If TDF is used in patients with renal insufficiency, the dose must be adjusted for creatinine clearance (<a href=\"image.htm?imageKey=GAST%2F71024\" class=\"graphic graphic_table graphicRef71024 \">table 1</a>). If TDF is stopped, patients should be switched to another nucleos(t)ide analogue that is not nephrotoxic. (See <a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management#H1521734005\" class=\"medical medical_review\">&quot;Hepatitis B virus: Overview of management&quot;, section on 'Antiviral therapy'</a> and <a href=\"topic.htm?path=entecavir-in-the-treatment-of-chronic-hepatitis-b-virus-infection\" class=\"medical medical_review\">&quot;Entecavir in the treatment of chronic hepatitis B virus infection&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">Tenofovir alafenamide</a><strong> (TAF)</strong> &ndash; TAF appears to have less renal toxicity compared with TDF, and is approved for use as monotherapy in patients with chronic HBV and an estimated glomerular filtration rate (eGFR) &gt;15 <span class=\"nowrap\">min/mL/1</span>.73m<sup>2</sup>. (See <a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management#H1024602452\" class=\"medical medical_review\">&quot;Hepatitis B virus: Overview of management&quot;, section on 'Choice of initial agent'</a>.)</p><p/><p class=\"bulletIndent1\">Safety data from the two trials comparing TDF with TAF include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Among hepatitis B e antigen (HBeAg)-positive patients, the mean increase in serum creatinine from baseline to 48 weeks was small in both groups; however, the increase was significantly smaller among the 581 HBeAg-positive patients receiving TAF compared with the 292 receiving TDF (0.01 versus 0.03 <span class=\"nowrap\">mg/dL)</span>. Patients receiving TAF also had a significantly smaller decrease in the eGFR (&ndash;0.6 versus &ndash;5.4 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Among HBeAg-negative patients (285 receiving TAF and 141 receiving TDF), there was no significant difference in the mean increase in serum creatinine from baseline to week 48 (0.01 versus 0.02 <span class=\"nowrap\">mg/dL)</span> [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/1\" class=\"abstract_t\">1</a>]. However, patients receiving TAF had a significantly lower median decrease in the eGFR (&ndash;1.8 versus &ndash;4.8 <span class=\"nowrap\">mL/min),</span> and a significantly smaller increase in markers of proximal tubular dysfunction (urine retinol-binding-protein-to-creatinine ratio, and urine B<sub>2</sub> microglobulin-to-creatinine ratio).</p><p/><p>A more detailed description of these trials is found above. (See <a href=\"#H1580558325\" class=\"local\">'Effect of tenofovir alafenamide on virologic outcomes'</a> above.)</p><p class=\"headingAnchor\" id=\"H796804532\"><span class=\"h3\">Bone density</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate</a><strong> (TDF)</strong> <strong>&ndash;</strong> TDF may reduce bone density in patients with chronic HBV monoinfection [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/11,14,39,41\" class=\"abstract_t\">11,14,39,41</a>]. As examples:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In one study that followed 280 patients receiving TDF, with or without <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>, the mean change in bone mineral density at week 240 was &ndash;0.98 and &ndash;2.54 percent at the spine and hip, respectively [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In another study, which analyzed an administrative database of 53,500 patients with chronic HBV who were followed for three years, there was a low rate of hip and spine fractures in those who received nucleos(t)ide analogue therapy (19 of 7046) [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/39\" class=\"abstract_t\">39</a>]. However, the 689 patients who were exposed to nucleotide analogues (tenofovir, <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a>) had an increased risk of hip fracture (but not vertebral fracture) compared with the 6357 who received nucleoside analogues such as <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> (hazard ratio [HR] 5.69, 95% CI 1.98-16.39), and the 46,454 who received no antiviral therapy (HR 3.84, 95% CI 1.26-11.70).</p><p/><p class=\"bulletIndent1\">Decreases in bone density appear to be related to an increased loss of phosphate through the kidneys. Although the effect appears to be mild, the effect is more prominent in children, and therefore tenofovir should generally be avoided in children.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">Tenofovir alafenamide</a><strong> (TAF)</strong> &ndash; TAF has less effect on bone density compared with TDF. Safety data from the two clinical trials described above include (see <a href=\"#H1580558325\" class=\"local\">'Effect of tenofovir alafenamide on virologic outcomes'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When changes in bone density were compared among 581 HBeAg-positive patients receiving TAF with 292 HBeAg-positive patients receiving TDF, the mean change in bone mineral density at the hip was &ndash;0.10 versus &ndash;1.72 percent (adjusted difference 1.62 percent, 95% CI 1.27-1.96), and the mean change at the spine was &ndash;0.42 percent versus &ndash;2.29 percent at week 48 (adjusted difference 1.88 percent, 95% CI 1.44-2.31) [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When HBeAg-negative patients were compared (285 receiving TAF versus 141 receiving TDF), the mean change in bone mineral density at the hip was &ndash;0.29 percent versus &ndash;2.16 percent (adjusted difference 1.87 percent; 95% CI 1.42-2.32), and the mean change at the spine was &ndash;0.88 percent versus &ndash;2.51 percent at week 48 (adjusted difference 1.64 percent; 95% CI 1.01-2.27) [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"headingAnchor\" id=\"H1228184470\"><span class=\"h1\">ADEFOVIR</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">Adefovir</a> dipivoxil is a nucleotide analog of adenosine monophosphate that can inhibit reverse transcriptase and DNA polymerase activity [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/42,43\" class=\"abstract_t\">42,43</a>]. The most important role of adefovir is in the treatment of patients with lamivudine-resistant hepatitis B virus (HBV), preferably in combination with another nucleoside analogue. However, this role has largely been replaced by tenofovir, which is more potent and has a higher barrier to resistance. If used, adefovir is administered orally, and the dose is 10 mg daily. Patients with impaired renal function should have the dosing interval adjusted (<a href=\"image.htm?imageKey=GAST%2F71024\" class=\"graphic graphic_table graphicRef71024 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H4066122240\"><span class=\"h2\">Effect on virologic outcomes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Monotherapy with <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> (10 mg daily for 48 weeks) in patients with HBeAg-positive or HBeAg-negative chronic HBV infection has been associated with a 3 to 4 log10 reduction in mean HBV DNA levels. In patients with lamivudine-resistant chronic HBV infection, the addition of adefovir is associated with a lower risk of adefovir resistance than a switch to adefovir monotherapy. </p><p class=\"headingAnchor\" id=\"H1408506613\"><span class=\"h3\">Patients who are nucleoside naive</span></p><p class=\"headingAnchor\" id=\"H2270429396\"><span class=\"h4\">HBeAg-positive chronic hepatitis B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> in HBeAg-positive patients has been demonstrated in at least two large, placebo-controlled trials [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/44,45\" class=\"abstract_t\">44,45</a>]. The largest trial included 515 nucleoside-na&iuml;ve patients with compensated liver disease who were randomly assigned to two doses of adefovir (10 or 30 mg) or placebo [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/44\" class=\"abstract_t\">44</a>]. The study was open to treatment-naive patients as well as those who had failed interferon. The following benefits were observed compared with placebo in the 10 mg group (the approved dose) after 48 weeks of treatment; all results were statistically significant:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histologic improvement, defined as decrease in Knodell histologic inflammatory score by at least two points with no worsening in fibrosis (53 versus 25 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improvement in fibrosis based on ranked assessment (41 versus 24 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HBeAg seroconversion (ie, disappearance of HBeAg and appearance of anti-HBe, 12 versus 6 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HBeAg loss (24 versus 11 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HBV DNA reduction to &lt;400 <span class=\"nowrap\">copies/mL</span> (approximately 80 international <span class=\"nowrap\">units/mL;</span> 21 versus 0 percent)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Percentage of patients achieving normalization of alanine aminotransferase (ALT) (48 versus 16 percent)</p><p/><p>HBeAg seroconversion and histologic improvement were more likely in patients with higher baseline ALT values.</p><p>The group that received 30 mg of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> had a higher rate of HBeAg seroconversion (14 versus 12 percent), but the difference was not significant. Furthermore, the 30 mg dose was associated with an increase in serum creatinine (&gt;0.5 <span class=\"nowrap\">mg/dL)</span> in 8 percent of patients.</p><p>A follow-up report described the efficacy of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> in a subset of 65 patients who received the 10 mg dose and were observed for up to five years [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/46\" class=\"abstract_t\">46</a>]. The probabilities of HBeAg loss and seroconversion were 58 and 48 percent, respectively.</p><p>Adefovir-resistant mutations (A181V and N236T) developed in 13 patients (30 percent). Nephrotoxicity, defined as reproducible increase in creatinine by &gt;0.5 <span class=\"nowrap\">mg/dL,</span> was observed in six patients, and two patients had confirmed hypophosphatemia.</p><p class=\"headingAnchor\" id=\"H2045244976\"><span class=\"h4\">HBeAg-negative chronic hepatitis B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A controlled trial included 185 patients with HBeAg-negative chronic hepatitis B who were randomly assigned to <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> (10 mg daily) or placebo for 48 weeks [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/47\" class=\"abstract_t\">47</a>]. At the end of treatment, patients who had received adefovir were significantly more likely to have improvement in liver histology (77 versus 33 percent), undetectable HBV DNA (51 versus 0 percent), and normalization of ALT levels (72 versus 29 percent). No treatment-related adverse events were observed.</p><p>An update of this study included data on 55 patients who completed four years and 70 patients who completed five years of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> treatment [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/48\" class=\"abstract_t\">48</a>]. Based on modified intention-to-treat analysis, normalization of ALT was observed in 73 and 69 percent, and undetectable-HBV DNA by polymerase chain reaction (PCR) assay in 73 and 67 percent, respectively. Forty-six patients had repeat liver biopsies at the end of the study. Ranked assessment of liver histology indicated improvement in necroinflammation in &gt;80 percent and fibrosis in &gt;70 percent of patients in both groups. Significant improvement in fibrosis (a decrease in fibrosis score by &ge;2 points) was observed in 7 of 12 patients who had bridging fibrosis or cirrhosis at baseline.</p><p>The cumulative probability of adefovir-resistant mutations rtN236T and rtA181V increased from 0 in year 1 to 3, 11, 18, and 29 percent in years 2, 3, 4, and 5, respectively. Four (3 percent) patients had confirmed increase in serum creatinine by &ge;0.5 <span class=\"nowrap\">mg/dL</span> above baseline; nephrotoxicity resolved in one patient after permanent discontinuation of treatment, and remained unresolved in the other three patients.</p><p>A report of 33 patients without cirrhosis who discontinued treatment after four to five years of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> and were followed for 5.5 years found that all patients had viral relapse (detection of HBV DNA by PCR) and 25 had biochemical relapse [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/49\" class=\"abstract_t\">49</a>]. During follow-up, 18 (55 percent) patients achieved a sustained response (HBV DNA &lt;2000 international <span class=\"nowrap\">unit/mL</span> and normal ALT), and 13 cleared HBsAg. These data suggest that sustained clinical remission can be achieved in more than 50 percent of patients with HBeAg-negative chronic hepatitis B after four to five years of continued antiviral therapy.</p><p class=\"headingAnchor\" id=\"H2410807718\"><span class=\"h3\">Patients with lamivudine resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The efficacy of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> in patients with lamivudine-resistant HBV infection has been demonstrated in several clinical settings, including in those with decompensated liver disease or liver transplantation. The available data suggest that adefovir is associated with significant clinical improvement and reduction in HBV DNA in patients with all types of lamivudine-resistant mutations [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/50-54\" class=\"abstract_t\">50-54</a>].</p><p>However, the antiviral effect of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> is slow, and as many as 25 to 50 percent of patients have primary nonresponse [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/55\" class=\"abstract_t\">55</a>]. Add-on adefovir is preferred to a switch in patients with <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> resistance in reducing subsequent risk of adefovir resistance. </p><p class=\"headingAnchor\" id=\"H3663326617\"><span class=\"h2\">Safety</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Renal toxicity (a concern with the higher doses of <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a>) was uncommon in patients receiving the 10 mg dose except in those with decompensated cirrhosis or who had undergone liver transplantation. Renal toxicity appears to be more likely in patients who are older, have baseline renal insufficiency, have hypertension, <span class=\"nowrap\">and/or</span> have diabetes mellitus [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/56\" class=\"abstract_t\">56</a>]. Renal tubular dysfunction was observed in up to 15 percent of patients in one study of 42 patients treated for a mean of seven years [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/36\" class=\"abstract_t\">36</a>]. </p><p class=\"headingAnchor\" id=\"H2636208061\"><span class=\"h2\">Development of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resistance occurs at a slower rate during <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> treatment compared with <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a>. However, mutations conferring resistance to adefovir (rtN236T, A181V, and A181T) have been described [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/57-60\" class=\"abstract_t\">57-60</a>]. A study analyzing pooled data from all studies sponsored by the manufacturer concluded that A181T mutation was not associated with adefovir resistance [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/60\" class=\"abstract_t\">60</a>]. The rtA181T mutation leads to a stop codon mutation in the overlapping surface gene with resultant impairment in virion secretion [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/61\" class=\"abstract_t\">61</a>]. This may account for the low serum HBV DNA level associated with initial emergence of rtA181T mutation. </p><p>The cumulative rate of resistance was estimated to be 15 percent by 192 weeks in one report that included data from five studies [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/62\" class=\"abstract_t\">62</a>]. In one of the studies cited above in which 67 HBeAg-negative nucleoside-na&iuml;ve patients received <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> monotherapy, the cumulative rate of resistance was 0, 3, 11, 18, and 29 percent at weeks 48, 96, 144, 192, and 240, respectively [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/48\" class=\"abstract_t\">48</a>]. In the study of HBeAg-positive nucleoside-na&iuml;ve patients, the cumulative rate of resistance was approximately 30 percent after five years of treatment.</p><p>In vitro and human studies found that adefovir-resistant HBV mutants are susceptible to tenofovir and <a href=\"topic.htm?path=entecavir-drug-information\" class=\"drug drug_general\">entecavir</a> [<a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/55\" class=\"abstract_t\">55</a>], although the double variant, A181V and N236T, is less responsive to tenofovir. </p><p class=\"headingAnchor\" id=\"H3178671736\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-management-of-hepatitis-b\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Management of hepatitis B&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate</a> (TDF) and <a href=\"topic.htm?path=tenofovir-alafenamide-drug-information\" class=\"drug drug_general\">tenofovir alafenamide</a> (TAF) are nucleotide reverse transcriptase inhibitors that have activity against hepatitis B virus (HBV) and HIV. Compared with <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> (another nucleotide reverse transcriptase inhibitor), tenofovir has more potent antiviral activity and a better safety profile. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H2071463476\" class=\"local\">'Formulations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with hepatitis B e antigen (HBeAg)-positive chronic HBV who had not previously received treatment, TDF (300 mg daily) was significantly more effective than <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> (10 mg daily) at reducing serum HBV DNA levels and achieving normalization of serum alanine aminotransferase (ALT). However, the degree of histologic benefit and the proportion of patients achieving HBeAg seroconversion were similar. (See <a href=\"#H2\" class=\"local\">'Patients with HBeAg-positive chronic hepatitis B'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with HBeAg-negative chronic HBV who have not previously received treatment, TDF (300 mg daily) was significantly more effective than <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a> (10 mg daily) at reducing HBV DNA. The proportions of patients achieving normalization of serum ALT and improvement in histology were similar. (See <a href=\"#H3\" class=\"local\">'Patients with HBeAg-negative chronic hepatitis B'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Studies of patients who had previously received treatment with other nucleos(t)ide analogues found that TDF is effective in suppressing lamivudine-resistant HBV, and TDF monotherapy is as effective as TDF combined with <a href=\"topic.htm?path=emtricitabine-drug-information\" class=\"drug drug_general\">emtricitabine</a>. However, there may be a slower decline in HBV DNA levels when tenofovir is used to treat patients with virus that has dual resistance mutations to <a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">adefovir</a>. (See <a href=\"#H5\" class=\"local\">'Patients with previous exposure to other nucleos(t)ide analogues'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TAF (25 mg daily) has been evaluated in HBeAg-positive and HBeAg-negative patients with chronic HBV. This agent has been found to have similar efficacy to TDF in both treatment-na&iuml;ve and treatment-experienced patients at 48 weeks. (See <a href=\"#H1580558325\" class=\"local\">'Effect of tenofovir alafenamide on virologic outcomes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients receiving tenofovir for the treatment of chronic HBV infection (both those who are treatment-na&iuml;ve and those with <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a> resistance prior to treatment), no signature tenofovir-resistance mutations have been identified. (See <a href=\"#H3583698056\" class=\"local\">'Risk of resistance'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tenofovir is associated with renal and bone toxicity; however, TAF appears to have significantly less effect on kidney function and bone mineral density compared with TDF. (See <a href=\"#H7\" class=\"local\">'Safety'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=adefovir-drug-information\" class=\"drug drug_general\">Adefovir</a> dipivoxil is a nucleotide analog of adenosine monophosphate, which can inhibit reverse transcriptase and DNA polymerase activity. However, this agent has been replaced by tenofovir, which is more potent and has a higher barrier to resistance. (See <a href=\"#H1228184470\" class=\"local\">'Adefovir'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/1\" class=\"nounderline abstract_t\">Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:185.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/2\" class=\"nounderline abstract_t\">Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:196.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/3\" class=\"nounderline abstract_t\">Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/4\" class=\"nounderline abstract_t\">Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140:132.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/5\" class=\"nounderline abstract_t\">Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381:468.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/6\" class=\"nounderline abstract_t\">Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015; 60:1457.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/7\" class=\"nounderline abstract_t\">Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014; 146:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/8\" class=\"nounderline abstract_t\">Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2:266.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/9\" class=\"nounderline abstract_t\">Manns M, Jeffers L, Dalekos T, et al. The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treatment for chronic hepatitis B (CHB) (abstract). J Hepatol 2008; (Suppl):S32.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/10\" class=\"nounderline abstract_t\">van B&ouml;mmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51:73.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/11\" class=\"nounderline abstract_t\">Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146:980.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/12\" class=\"nounderline abstract_t\">van Bommel F, Mauss S, Schurmann D, et al. No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years (abstract). Hepatology 2006; 44(Suppl 1):549A.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/13\" class=\"nounderline abstract_t\">Wang HL, Lu X, Yang X, Ning Q. Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016; 40:447.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/14\" class=\"nounderline abstract_t\">Fung S, Kwan P, Fabri M, et al. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol 2017; 66:11.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/15\" class=\"nounderline abstract_t\">van B&ouml;mmel F, Z&ouml;llner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44:318.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/16\" class=\"nounderline abstract_t\">van B&ouml;mmel F, W&uuml;nsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/17\" class=\"nounderline abstract_t\">van B&ouml;mmel F, Berg T. Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology 2005; 42:239.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/18\" class=\"nounderline abstract_t\">Schildgen O, Hartmann H, Gerlich WH. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol 2006; 41:245.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/19\" class=\"nounderline abstract_t\">Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139:1207.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/20\" class=\"nounderline abstract_t\">Berg T, Zoulim F, Moeller B, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014; 60:715.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/21\" class=\"nounderline abstract_t\">Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48:391.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/22\" class=\"nounderline abstract_t\">van B&ouml;mmel F, Trojan J, Deterding K, et al. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. Antivir Ther 2012; 17:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/23\" class=\"nounderline abstract_t\">Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53:774.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/24\" class=\"nounderline abstract_t\">Buti M, Fung S, Gane E, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int 2015; 9:243.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/25\" class=\"nounderline abstract_t\">Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol 2016; 22:319.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/26\" class=\"nounderline abstract_t\">Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015; 121:3631.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/27\" class=\"nounderline abstract_t\">Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59:434.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/28\" class=\"nounderline abstract_t\">Corsa AC, Liu Y, Flaherty JF, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol 2014; 12:2106.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/29\" class=\"nounderline abstract_t\">Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8&nbsp;years of treatment. J Viral Hepat 2017; 24:68.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/30\" class=\"nounderline abstract_t\">Shirvani-Dastgerdi E, Winer BY, Celi&agrave;-Terrassa T, et al. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017; 67:246.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/31\" class=\"nounderline abstract_t\">Sheldon J, Camino N, Rod&eacute;s B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/32\" class=\"nounderline abstract_t\">Delaney WE 4th, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/33\" class=\"nounderline abstract_t\">Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 2013; 24:1519.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/34\" class=\"nounderline abstract_t\">Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22:99.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/35\" class=\"nounderline abstract_t\">Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/36\" class=\"nounderline abstract_t\">Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/37\" class=\"nounderline abstract_t\">Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014; 39:35.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/38\" class=\"nounderline abstract_t\">Lampertico P, Chan HL, Janssen HL, et al. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther 2016; 44:16.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/39\" class=\"nounderline abstract_t\">Wong GL, Tse YK, Wong VW, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 2015; 62:684.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/40\" class=\"nounderline abstract_t\">Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 2016; 63:284.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/41\" class=\"nounderline abstract_t\">Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49:S185.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/42\" class=\"nounderline abstract_t\">Gilson RJ, Chopra KB, Newell AM, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6:387.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/43\" class=\"nounderline abstract_t\">Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29:1863.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/44\" class=\"nounderline abstract_t\">Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/45\" class=\"nounderline abstract_t\">Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44:108.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/46\" class=\"nounderline abstract_t\">Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48:750.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/47\" class=\"nounderline abstract_t\">Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/48\" class=\"nounderline abstract_t\">Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/49\" class=\"nounderline abstract_t\">Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143:629.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/50\" class=\"nounderline abstract_t\">Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/51\" class=\"nounderline abstract_t\">Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/52\" class=\"nounderline abstract_t\">Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/53\" class=\"nounderline abstract_t\">Peters MG, Hann Hw Hw, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/54\" class=\"nounderline abstract_t\">Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/55\" class=\"nounderline abstract_t\">Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/56\" class=\"nounderline abstract_t\">Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50:727.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/57\" class=\"nounderline abstract_t\">Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/58\" class=\"nounderline abstract_t\">Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39:1085.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/59\" class=\"nounderline abstract_t\">Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006; 20:2229.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/60\" class=\"nounderline abstract_t\">Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47:492.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/61\" class=\"nounderline abstract_t\">Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48:88.</a></li><li><a href=\"https://www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection/abstract/62\" class=\"nounderline abstract_t\">Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B (abstract). J Hepatol 2005; 42 (Suppl 2):17A.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3656 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1189182665\" id=\"outline-link-H1189182665\">TENOFOVIR</a><ul><li><a href=\"#H2071463476\" id=\"outline-link-H2071463476\">Formulations</a></li><li><a href=\"#H1621336408\" id=\"outline-link-H1621336408\">Effect of tenofovir disoproxil fumarate on virologic outcomes</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">- Patients with HBeAg-positive chronic hepatitis B</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">- Patients with HBeAg-negative chronic hepatitis B</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Patients with previous exposure to other nucleos(t)ide analogues</a><ul><li><a href=\"#H796804192\" id=\"outline-link-H796804192\">Lamivudine resistance</a></li><li><a href=\"#H796804199\" id=\"outline-link-H796804199\">Adefovir resistance</a></li></ul></li><li><a href=\"#H1121393047\" id=\"outline-link-H1121393047\">- Patients with spontaneous exacerbation</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- In combination with other drugs</a></li></ul></li><li><a href=\"#H1580558325\" id=\"outline-link-H1580558325\">Effect of tenofovir alafenamide on virologic outcomes</a></li><li><a href=\"#H1630287554\" id=\"outline-link-H1630287554\">Effect on clinical outcomes</a><ul><li><a href=\"#H2794773517\" id=\"outline-link-H2794773517\">- Regression of fibrosis and cirrhosis</a></li><li><a href=\"#H2409414740\" id=\"outline-link-H2409414740\">- Reduced risk of hepatocellular carcinoma</a></li></ul></li><li><a href=\"#H3583698056\" id=\"outline-link-H3583698056\">Risk of resistance</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Safety</a><ul><li><a href=\"#H796804526\" id=\"outline-link-H796804526\">- Renal insufficiency and renal tubular dysfunction</a></li><li><a href=\"#H796804532\" id=\"outline-link-H796804532\">- Bone density</a></li></ul></li></ul></li><li><a href=\"#H1228184470\" id=\"outline-link-H1228184470\">ADEFOVIR</a><ul><li><a href=\"#H4066122240\" id=\"outline-link-H4066122240\">Effect on virologic outcomes</a><ul><li><a href=\"#H1408506613\" id=\"outline-link-H1408506613\">- Patients who are nucleoside naive</a><ul><li><a href=\"#H2270429396\" id=\"outline-link-H2270429396\">HBeAg-positive chronic hepatitis B</a></li><li><a href=\"#H2045244976\" id=\"outline-link-H2045244976\">HBeAg-negative chronic hepatitis B</a></li></ul></li><li><a href=\"#H2410807718\" id=\"outline-link-H2410807718\">- Patients with lamivudine resistance</a></li></ul></li><li><a href=\"#H3663326617\" id=\"outline-link-H3663326617\">Safety</a></li><li><a href=\"#H2636208061\" id=\"outline-link-H2636208061\">Development of resistance</a></li></ul></li><li><a href=\"#H3178671736\" id=\"outline-link-H3178671736\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/3656|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/71024\" class=\"graphic graphic_table\">- Chronic HBV dose adjustment</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=combination-therapy-for-chronic-hepatitis-b-virus-infection\" class=\"medical medical_review\">Combination therapy for chronic hepatitis B virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=entecavir-in-the-treatment-of-chronic-hepatitis-b-virus-infection\" class=\"medical medical_review\">Entecavir in the treatment of chronic hepatitis B virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-b-virus-reactivation-associated-with-immunosuppressive-therapy\" class=\"medical medical_review\">Hepatitis B virus reactivation associated with immunosuppressive therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-b-virus-clinical-manifestations-and-natural-history\" class=\"medical medical_review\">Hepatitis B virus: Clinical manifestations and natural history</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-b-virus-overview-of-management\" class=\"medical medical_review\">Hepatitis B virus: Overview of management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antiretroviral-agents-used-to-treat-hiv\" class=\"medical medical_review\">Overview of antiretroviral agents used to treat HIV</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-management-of-hepatitis-b\" class=\"medical medical_society_guidelines\">Society guideline links: Management of hepatitis B</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=standard-and-pegylated-interferon-for-chronic-hepatitis-b-virus-infection\" class=\"medical medical_review\">Standard and pegylated interferon for chronic hepatitis B virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-chronic-hepatitis-b-in-the-hiv-infected-patient\" class=\"medical medical_review\">Treatment of chronic hepatitis B in the HIV-infected patient</a></li></ul></div></div>","javascript":null}